Lometrexol hydrate

A GART inhibitor

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥2500.00

2000.00

- +
5mg

￥7450.00

5960.00

- +
10mg

￥11875.00

9500.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajcx17364
CAS: 1435784-14-7
别名: 洛美曲索水合物,DDATHF hydrate
分子式: C21H27N5O7
分子量: 461.47
纯度: >98%
溶解度: DMF: 5 mg/ml,DMSO: 20 mg/ml,DMSO:PBS(pH7.2) (1:1): 0.5 mg/ml
储存: Store at -20°C
库存: 现货

Background

Glycinamide ribonucleotide formyltransferase (GART) is a folate-dependent enzyme required for de novo purine synthesis. Lometrexol is a folate analog antimetabolite with antineoplastic activity.^1,2 At nanomolar conentrations, it inhibits GART preventing de novo purine synthesis, inhibiting DNA synthesis, arresting cells in the S phase of the cell cycle, and inhibiting tumor cell proliferation.³

1.Beardsley, G.P., Moroson, B.A., Taylor, E.C., et al.A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesisJ. Biol. Chem.264(1)328-333(1989) 2.Pizzorno, G., Moroson, B.A., Cashmore, A.R., et al.(6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cellsCancer Res.51(9)2291-2295(1991) 3.Bronder, J.L., and Moran, R.G.Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 functionCancer Res.62(18)5236-5241(2002)